OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer - Full Text View

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

This study has been completed.

Sponsors and Collaborators:	OSI Pharmaceuticals National Cancer Institute of Canada
Information provided by:	OSI Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00036647

Purpose

The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).

Condition	Intervention	Phase
Carcinoma, Non-Small-Cell Lung	Drug: Tarceva (erlotinib HCl, OSI-774 )	Phase III

MedlinePlus related topics:

Cancer Lung Cancer

ChemIDplus related topics:

Erlotinib Erlotinib hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title:	A Randomized Placebo Controlled Study of OSI-744 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease

Further study details as provided by OSI Pharmaceuticals:

Estimated Enrollment:	700
Study Start Date:	October 2001
Estimated Study Completion Date:	January 2003

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Clinical diagnosis of stage IIIB or IV non-small cell lung cancer.
Must have evidence of disease (clinical or radiological).
Have failed 1 but no more than 2 prior chemotherapy regimens, have recovered from any side effects and have not had any chemotherapy for at least 21 days.
If the patient has had surgery, the surgery was at least 2 weeks ago.
Patients whose cancer has spread to their brain or central nervous system are eligible, providing that they have been on stable dose of steroids for at least 4 weeks and are free of symptoms.
If the patient received radiation therapy, treatment was at least 4 weeks ago.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036647

Show 97 Study Locations

Sponsors and Collaborators

OSI Pharmaceuticals

National Cancer Institute of Canada

Investigators


Study Chair:	Frances Shepherd, M.D.

More Information

Study ID Numbers:	OSI-774-BR.21
First Received:	May 13, 2002
Last Updated:	December 16, 2005
ClinicalTrials.gov Identifier:	NCT00036647
Health Authority:	United States: Food and Drug Administration

Keywords provided by OSI Pharmaceuticals:

Non-Small Cell Lung Cancer

Tarceva

EGFR

erlotinib

Study placed in the following topic categories:

Erlotinib

Thoracic Neoplasms

Non-small cell lung cancer

Respiratory Tract Diseases

Lung Neoplasms

Lung Diseases

Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Neoplasms, Glandular and Epithelial

Carcinoma

Additional relevant MeSH terms:

Respiratory Tract Neoplasms

Neoplasms

Neoplasms by Site

Neoplasms by Histologic Type

Molecular Mechanisms of Pharmacological Action

Enzyme Inhibitors

Protein Kinase Inhibitors

Pharmacologic Actions

ClinicalTrials.gov processed this record on August 29, 2008